Zogenix, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (2006)
Status: Acquired by UCB (2022)

Organization Overview

First Clinical Trial
2006
NCT02117141
First Marketed Drug
2020
fenfluramine (Pondimin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zogenix, Inc. | ZOGENIX INC | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Active Ingredients

Marketed Drugs (1)

fenfluramine (Pondimin) (2020)

Drugs in Phase 4 Trials (2)

fenfluramine (Pondimin) (14 trials)

sumatriptan (zecuity) (2 trials)

Drugs in Phase 3 Trials (2)

Key: Zogenix, Inc. (1) Acquired (1)

deoxythymidine (2 trials)

hydrocodone (hycodan) (8 trials)

Drugs in Phase 2 Trials (1)

apap (1 trial)

Drugs in Phase 1 Trials (2)

ethanol (1 trial)

risperidone (risperdal) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Brain Diseases (Phase 3)

Chronic Pain (Phase 3)

Epilepsies, Myoclonic (Phase 3)

Epilepsy (Phase 3)

Epilepsy, Reflex (Phase 3)

Lennox Gastaut Syndrome (Phase 3)

Liver Diseases (Phase 1)

Low Back Pain (Phase 3)

Migraine Disorders (Phase 4)

Osteoarthritis (Phase 2)

Pain, Postoperative (Phase 2)

Psychotic Disorders (Phase 1)

Renal Insufficiency (Phase 1)

Schizophrenia (Phase 1)

Seizures (Phase 3)

Spasms, Infantile (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial APIs: 7